These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 24817369

  • 1. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
    Kasai K, Kooka Y, Suzuki Y, Suzuki A, Oikawa T, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Takikawa Y.
    Ann Surg Oncol; 2014 Oct; 21(11):3638-45. PubMed ID: 24817369
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
    Cancer; 2012 Jul 01; 118(13):3302-10. PubMed ID: 22072099
    [Abstract] [Full Text] [Related]

  • 3. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
    Marumoto M, Yamasaki T, Marumoto Y, Saeki I, Harima Y, Urata Y, Hidaka I, Ishikawa T, Takami T, Segawa M, Yamaguchi Y, Uchida K, Terai S, Sakaida I.
    Hepatogastroenterology; 2014 Jul 01; 61(129):162-7. PubMed ID: 24895814
    [Abstract] [Full Text] [Related]

  • 4. Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.
    Yashima Y, Sato S, Kawai T, Sugimoto T, Sato T, Kanda M, Obi S.
    Hepatol Int; 2015 Jan 01; 9(1):142-8. PubMed ID: 25788388
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
    Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
    Int J Clin Oncol; 2011 Jun 01; 16(3):221-9. PubMed ID: 21132451
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    Okita K, Yamasaki T, Hamabe S, Saeki I, Harima Y, Terai S, Sakaida I.
    Hepatogastroenterology; 2012 Jun 01; 59(114):533-7. PubMed ID: 22353519
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
    Wu J, Huang WJ, Wang HY, Wang YF, Peng BG, Zhou Q.
    Med Oncol; 2015 Mar 01; 32(3):65. PubMed ID: 25691293
    [Abstract] [Full Text] [Related]

  • 10. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.
    Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R, Nakagawa H, Asaoka Y, Kondo Y, Yamashiki N, Goto T, Shiina S, Omata M, Yoshida H, Koike K.
    J Gastroenterol; 2012 Oct 01; 47(10):1152-9. PubMed ID: 22438097
    [Abstract] [Full Text] [Related]

  • 11. [A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU].
    Hasuike Y, Motoori M, Hattori T, Fujita J, Mishima H, Sawamura T, Nishishou I, Kikkawa N, Sai H, Hosoki T, Mitomo M.
    Gan To Kagaku Ryoho; 1999 Oct 01; 26(12):1909-12. PubMed ID: 10560423
    [Abstract] [Full Text] [Related]

  • 12. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
    Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D'Angelica MI, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR.
    Ann Surg Oncol; 2014 Aug 01; 21(8):2675-83. PubMed ID: 24664624
    [Abstract] [Full Text] [Related]

  • 13. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.
    Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM.
    Ann Surg Oncol; 2013 Nov 01; 20(12):3779-86. PubMed ID: 23846786
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhao R, Zhou J, Miao Z, Xiong X, Wei W, Li S, Guo R.
    Front Immunol; 2024 Nov 01; 15():1397827. PubMed ID: 38799453
    [Abstract] [Full Text] [Related]

  • 15. [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
    Yokoo H, Kamiyama T, Nakagawa T, Nakanishi K, Tahara M, Fukumori D, Kamachi H, Matsushita M, Todo S.
    Gan To Kagaku Ryoho; 2009 Nov 01; 36(12):2400-3. PubMed ID: 20037436
    [Abstract] [Full Text] [Related]

  • 16. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR.
    Cancer; 2016 Mar 01; 122(5):758-65. PubMed ID: 26695839
    [Abstract] [Full Text] [Related]

  • 17. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.
    Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, McMasters KM, Scoggins CR, Martin RC.
    Ann Surg Oncol; 2011 Feb 01; 18(2):431-8. PubMed ID: 20862554
    [Abstract] [Full Text] [Related]

  • 18. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M, Kobayashi Y, Urawa N, Yamamoto M, Mifuji R, Araki J, Tanaka H, Horiike S, Itani T, Furjita N, Konishi M, Iwasa M, Kaito M, Adachi Y.
    Hepatogastroenterology; 2007 Mar 01; 54(74):518-21. PubMed ID: 17523311
    [Abstract] [Full Text] [Related]

  • 19. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).
    Inaba Y, Arai Y, Yamaura H, Sato Y, Najima M, Aramaki T, Sone M, Kumada T, Tanigawa N, Anai H, Yoshioka T, Ikeda M, Japan Interventional Radiology in Oncology Study Group (JIVROSG).
    Am J Clin Oncol; 2011 Feb 01; 34(1):58-62. PubMed ID: 20177362
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
    Patt YZ, Jones DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C.
    J Clin Oncol; 1996 Aug 01; 14(8):2311-5. PubMed ID: 8708722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.